anticonvulsant/hypoxia

FIELD OF THE INVENTION The present invention relates to 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, which is a compound of formula ##STR00002## and to pharmaceutically acceptable acid addition salts thereof. This compound is generically

BACKGROUND OF THE INVENTION Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive

BACKGROUND OF THE INVENTION Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive

FIELD OF THE INVENTION The present invention is generally related to compounds useful as adenosine receptor ligand and more particularly to compounds showing activity as modulators of the andenosine receptor system. BACKGROUND OF THE INVENTION Several compounds related to general formula I have been

BACKGROUND OF THE INVENTION The invention relates to the use of relatively short peptides, about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which include preferably one to two or more

BACKGROUND OF THE INVENTION The invention relates to the use of relatively short peptides, about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturaly available peptides, and which include preferably one to two or more

FEATURES OF THE INVENTION The present invention relates to novel dibenz[b,e]oxepin derivatives useful for prevention and treatment of cerebral diseases caused by hypoxia. TECHNICAL BACKGROUND The brain, different from other organs, exists under particular environment such that it is dipped in

This invention relates to novel and therapeutically valuable compounds of the formula ##SPC2## And pharmaceutically acceptable acid addition salts thereof. In the above formula, R.sup.1 is H or CH.sub.3 ; R.sup.2 is CH.sub.3 or C.sub.2 H.sub.5, or R.sup.1 and R.sup.2 combinedly represent

BACKGROUND OF THE INVENTION NMDA AMPA Receptors Excessive excitation by neurotransmitters can cause the degeneration and death of neurons. It is believed that this degeneration is in part mediated by the excitotoxic actions of the excitotoxic amino acids (EAA) glutamate and aspartate at the